Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Free Cash Flow: 2012-2025

Historic Free Cash Flow for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to $30.4 million.

  • CorMedix's Free Cash Flow rose 322.19% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 234.06%. This contributed to the annual value of -$50.7 million for FY2024, which is 30.96% down from last year.
  • Per CorMedix's latest filing, its Free Cash Flow stood at $30.4 million for Q3 2025, which was up 1.28% from $30.0 million recorded in Q2 2025.
  • CorMedix's 5-year Free Cash Flow high stood at $30.4 million for Q3 2025, and its period low was -$17.4 million during Q1 2024.
  • Over the past 3 years, CorMedix's median Free Cash Flow value was -$8.0 million (recorded in 2023), while the average stood at $2.4 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 308.37% in 2021, then surged by 322.19% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Free Cash Flow stood at -$6.5 million in 2021, then climbed by 3.30% to -$6.3 million in 2022, then crashed by 54.23% to -$10.4 million in 2023, then crashed by 66.90% to -$5.6 million in 2024, then surged by 322.19% to $30.4 million in 2025.
  • Its last three reported values are $30.4 million in Q3 2025, $30.0 million for Q2 2025, and $19.7 million during Q1 2025.